Statistics for Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth
Total visits
| views | |
|---|---|
| Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth | 0 |
Total visits per month
| views | |
|---|---|
| November 2023 | 0 |
| December 2023 | 0 |
| January 2024 | 0 |
| February 2024 | 0 |
| March 2024 | 0 |
| April 2024 | 0 |
| May 2024 | 0 |
Total Downloads
| views | |
|---|---|
| Inhibiting_the_glycerophosphodiesterase_EDI3.pdf | 2 |